Direct oral anticoagulants in pediatric venous thromboembolism: Review of approved products rivaroxaban and dabigatran

Overview of attention for article published in Frontiers in Pediatrics, October 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (62nd percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

policy: 1 policy source

Readers on

mendeley: 31 Mendeley

So far, Altmetric has seen 2 policy documents that reference this research output.

rivaroxaban

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 21 Sep 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

rivaroxaban - Clinical and Pharmacoeconomic Combined Report

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 14 Jul 2022

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity.